We provide the latest news
from the world of economics and finance
(RTTNews) - Viridian Therapeutics Inc. (VRDN) announced the pricing of an underwritten public offering with gross proceeds of about $150.0 million. Viridian said it is selling a total of about 7.14 million shares of common stock at a public offering price of $21.00 per share.
In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1.07 million shares of common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about January 22, 2024, subject to customary closing conditions.
Viridian plans to use the proceeds from the proposed underwritten public offering of its shares of common stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.